Datapoint: Gilead Scores Broader Breast Cancer Nod for Trodelvy

The FDA last week approved Gilead Sciences’ Trodelvy for the treatment of HR-positive, HER2-negative breast cancer in patients whose cancer has not responded to three previous therapies, including endocrine therapy. The nod will make Trodelvy available to a broader patient group, as a majority of breast cancer patients have the HR-positive, HER2-negative form of the disease. Trodelvy is already approved to treat triple-negative breast cancer, an indication for which it holds covered or better status for 91% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 2/6/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today